These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36713546)

  • 1. Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world.
    Fang M; Hang Q; Jiang H; Cai L; Hu J; Ying H; Gu Q; Yu X; Liu J; Lai X
    Front Oncol; 2022; 12():1055610. PubMed ID: 36713546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 3. An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer.
    Qi Y; Gu L; Shen J; Yao Y; Zhao Y; Lu S; Chen Z
    Front Oncol; 2023; 13():1194100. PubMed ID: 37655106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
    Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
    J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Meta-Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer.
    Sun X; Kang T; Liu B; Zhang Y; Huang G
    Clin Respir J; 2024 Oct; 18(10):e70019. PubMed ID: 39359047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review.
    Yin C; Hu B; Yang X; Kou L; Tian B; Wang C; Li S; Liu B; Ge J
    World J Surg Oncol; 2023 Sep; 21(1):304. PubMed ID: 37749594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
    Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
    Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
    Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
    Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary experience of surgery after neoadjuvant immunotherapy combined with chemotherapy for stage-IIIB non-small cell lung cancer.
    Ding Y; Zhao X; Christopoulos P; Geraci TC; Fu Y
    J Thorac Dis; 2024 Jul; 16(7):4645-4654. PubMed ID: 39144346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
    [No Abstract]   [Full Text] [Related]  

  • 12. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.
    Jiang W; Zhou Y; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Guo H; Minervini F; Bongiolatti S; Yang N; Zhang Y; Tao M
    Transl Lung Cancer Res; 2022 Apr; 11(4):647-655. PubMed ID: 35529791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study.
    Zhao G; Zhang H; Xu F; Lu C; Zhu Q; Grossi F; Divisi D; Ma T; Gu J; Ge D
    Transl Lung Cancer Res; 2023 Jan; 12(1):141-149. PubMed ID: 36762056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.
    Wu J; Hou L; E H; Zhao Y; Yu X; Xu L; Ning Y; Deng J; Sun K; Zhang J; Wu C; Zhu Y; Zhao D; She Y; Su C; Chen C
    Lung Cancer; 2022 Mar; 165():115-123. PubMed ID: 35123154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
    Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
    Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
    Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
    Zhang C; Hong HZ; Wu YL; Zhong WZ
    JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer.
    Tao Y; Li X; Liu B; Wang J; Lv C; Li S; Wang Y; Chen J; Yan S; Wu N
    Front Oncol; 2023; 13():1135140. PubMed ID: 37256186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
    Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
    Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.